149 related articles for article (PubMed ID: 36984460)
1. The Use of Liquid Biopsy in the Molecular Analysis of Plasma Compared to the Tumour Tissue from a Patient with Brain Metastasis: A Case Report.
Aran V; Zogbi VM; Miranda RL; Andreiuolo F; Silva Canedo NH; Nazaré CV; Niemeyer Filho P; Neto VM
Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984460
[TBL] [Abstract][Full Text] [Related]
2. The predictive and prognostic significance of liquid biopsy in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: A prospective study.
Ding PN; Becker TM; Bray VJ; Chua W; Ma YF; Lynch D; Po J; Luk AWS; Caixeiro N; de Souza P; Roberts TL
Lung Cancer; 2019 Aug; 134():187-193. PubMed ID: 31319980
[TBL] [Abstract][Full Text] [Related]
3. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
[TBL] [Abstract][Full Text] [Related]
4. Dynamic monitoring of cerebrospinal fluid circulating tumor DNA to identify unique genetic profiles of brain metastatic tumors and better predict intracranial tumor responses in non-small cell lung cancer patients with brain metastases: a prospective cohort study (GASTO 1028).
Li M; Chen J; Zhang B; Yu J; Wang N; Li D; Shao Y; Zhu D; Liang C; Ma Y; Ou Q; Hou X; Chen L
BMC Med; 2022 Nov; 20(1):398. PubMed ID: 36372873
[TBL] [Abstract][Full Text] [Related]
5. Detection of circulating tumor DNA from non-small cell lung cancer brain metastasis in cerebrospinal fluid samples.
Ma C; Yang X; Xing W; Yu H; Si T; Guo Z
Thorac Cancer; 2020 Mar; 11(3):588-593. PubMed ID: 31944608
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer.
van 't Erve I; Greuter MJE; Bolhuis K; Vessies DCL; Leal A; Vink GR; van den Broek D; Velculescu VE; Punt CJA; Meijer GA; Coupé VMH; Fijneman RJA
J Mol Diagn; 2020 Dec; 22(12):1430-1437. PubMed ID: 32961317
[TBL] [Abstract][Full Text] [Related]
7. Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report.
Namløs HM; Zaikova O; Bjerkehagen B; Vodák D; Hovig E; Myklebost O; Boye K; Meza-Zepeda LA
BMC Cancer; 2017 Jan; 17(1):29. PubMed ID: 28061772
[TBL] [Abstract][Full Text] [Related]
8. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
Haupts A; Roth W; Hartmann N
Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
[TBL] [Abstract][Full Text] [Related]
9. The evolving role of liquid biopsy in lung cancer.
Malapelle U; Pisapia P; Pepe F; Russo G; Buono M; Russo A; Gomez J; Khorshid O; Mack PC; Rolfo C; Troncone G
Lung Cancer; 2022 Oct; 172():53-64. PubMed ID: 35998482
[TBL] [Abstract][Full Text] [Related]
10. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
11. Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.
Hicks JK; Saller J; Wang E; Boyle T; Gray JE
Lung Cancer; 2017 Sep; 111():135-138. PubMed ID: 28838384
[TBL] [Abstract][Full Text] [Related]
12. Combined Analysis of Concordance between Liquid and Tumor Tissue Biopsies for
Kagawa Y; Elez E; García-Foncillas J; Bando H; Taniguchi H; Vivancos A; Akagi K; García A; Denda T; Ros J; Nishina T; Baraibar I; Komatsu Y; Ciardiello D; Oki E; Kudo T; Kato T; Yamanaka T; Tabernero J; Yoshino T
Clin Cancer Res; 2021 May; 27(9):2515-2522. PubMed ID: 33602686
[TBL] [Abstract][Full Text] [Related]
13. Exhaled Breath Condensate (EBC) analysis of circulating tumour DNA (ctDNA) using a lung cancer specific UltraSEEK oncogene panel.
Ryan DJ; Toomey S; Smyth R; Madden SF; Workman J; Cummins R; Sheehan K; Fay J; Naidoo J; Breathnach OS; Morris PG; Grogan L; O'Brien ME; Sulaiman I; Hennessy BT; Morgan RK
Lung Cancer; 2022 Jun; 168():67-73. PubMed ID: 35526313
[TBL] [Abstract][Full Text] [Related]
14. Use of Liquid Biopsy in the Care of Patients with Non-Small Cell Lung Cancer.
Romero A; Serna-Blasco R; Calvo V; Provencio M
Curr Treat Options Oncol; 2021 Aug; 22(10):86. PubMed ID: 34424428
[TBL] [Abstract][Full Text] [Related]
15. Microarray Approach Combined with ddPCR: An Useful Pipeline for the Detection and Quantification of Circulating Tumour dna Mutations.
Galbiati S; Damin F; Ferraro L; Soriani N; Burgio V; Ronzoni M; Gianni L; Ferrari M; Chiari M
Cells; 2019 Jul; 8(8):. PubMed ID: 31344983
[No Abstract] [Full Text] [Related]
16. Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients.
Crisafulli G; Mussolin B; Cassingena A; Montone M; Bartolini A; Barault L; Martinetti A; Morano F; Pietrantonio F; Sartore-Bianchi A; Siena S; Di Nicolantonio F; Marsoni S; Bardelli A; Siravegna G
ESMO Open; 2019 Nov; 4(6):. PubMed ID: 32149725
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma.
Ito M; Miyata Y; Hirano S; Irisuna F; Kushitani K; Kai Y; Kishi N; Tsutani Y; Takeshima Y; Okada M
J Cancer Res Clin Oncol; 2022 Jun; 148(6):1419-1428. PubMed ID: 34218331
[TBL] [Abstract][Full Text] [Related]
18. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
19. Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer.
Villaflor V; Won B; Nagy R; Banks K; Lanman RB; Talasaz A; Salgia R
Oncotarget; 2016 Oct; 7(41):66880-66891. PubMed ID: 27602770
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
